Clinical Trials Directory
We are doing this study to compare 2 different options for preventing strokes for people who have atrial fibrillation. We want to find out if apixaban or aspirin is the better choice to help prevent future strokes for patients with atrial fibrillation and who had a recent brain hemorrhage.
If you join this study, you will receive a medicine called ASP546C through a vein every three weeks. You will also give blood and urine samples so doctors can check your health and how your body responds to the treatment. During the study, you will have regular scans such as CT or MRI to see how your cancer is changing.
This study has three parts: - Screening (up to 21 days): You'll get health checks like heart tests, scans, and blood work. - Study Drug Period (28-day cycles): You'll be randomly placed in one of two groups: - One group gets AZD3632 alone. -The other gets AZD3632 with another medicine called posaconazole. You'll have regular visits for tests and questions. - After Treatment: You'll have a safety check 30 days after your last dose, then visits every 12 weeks to see how your disease is doing.
In this study, people are placed into one of two groups based on certain features found in their genes. The first group, called Cohort 1, includes people who have low‑risk genetic signs. To be in this group, a person must have a mutated IGHV gene, must not have a 17p deletion, and must not have a TP53 mutation. All three conditions must be true. People in this group will first take a medicine called acalabrutinib for two cycles. After that, they will take a combination of acalabrutinib and venetoclax, called AV, for twelve more cycles. The second group, called Cohort 2, includes people who have any high‑risk genetic signs. This may include having an unmutated IGHV gene, a 17p deletion, a TP53 mutation, or a mix of these.
If you join this study, you will have a procedure where the study medicine is placed into the back of your eye. After this, you will return for follow up visits for up to five years so doctors can check how your eyes are doing. There will be about seventeen visits in total. At these visits, doctors will test your vision and examine your eyes to watch for changes and make sure the treatment is safe.
People may be able to join this study if they have a disease called eosinophilic esophagitis, or EoE, which can make it hard to swallow food. Before joining, they will have a screening visit and a procedure called an endoscopy with biopsies to see if they qualify. Participants will be placed into one of two groups by chance. One group will take a medicine called upadacitinib by mouth every day for 24 weeks. The other group will take a placebo, which has no active medicine, for 12 weeks and then switch to upadacitinib for 12 weeks. This allows everyone in the study to receive the study medicine at some point. During the study, participants will have regular checkups that include blood tests, vital sign measurements, questionnaires, and endoscopies with biopsies at the start of the study, at Week 12, and at Week 24. Researchers want to learn if upadacitinib can safely help reduce inflammation and improve symptoms in people with EoE.
Participants will first have a finger stick blood test to see if they have sickle cell trait. If they do, they may continue in the study by completing a health survey, having their height, weight, blood pressure, and heart rate measured, providing a blood sample, and giving a urine sample. Researchers will use this information to learn more about the health of people with sickle cell trait.
This study is testing a new medicine called MYK-224 to help people with a heart problem called HFpEF. That means their heart pumps well but does not relax properly. People in the study also have signs that their heart is not working normally. The study has four groups, called cohorts. Duke is only helping with Cohort 4, which will include about 160 people. These people will be split into four smaller groups. Three groups will get different amounts of the real medicine, and one group will get a fake medicine called a placebo. The treatment will last 20 weeks. A special team of doctors will check to make sure the medicine is safe and decide how much each group should get. To join the study, people must meet certain health rules.